Literature DB >> 11723414

Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.

P R Figueroa-Casas1, B Ettinger, E Delgado, A Javkin, C Vieder.   

Abstract

OBJECTIVE: Endometrial hyperplasia, an entity considered a precursor to endometrial carcinoma, frequently develops in women receiving unopposed estrogens. Progestins used concomitantly with estrogens can largely prevent endometrial hyperplasia and carcinoma. However, the ability of progestins to reverse endometrial hyperplasia induced by estrogens is less well recognized. The purpose of this study was to assess the medical reversal rate of endometrial hyperplasia that develops in women receiving unopposed estrogen replacement therapy (ERT).
DESIGN: Review of recent literature (1990-2000).
RESULTS: Based on four large series, more than 90% of endometrial hyperplasia caused by ERT can be reversed by medical treatment. Discontinuation of estrogen and oral administration of 10 mg/day of medroxyprogesterone acetate continuously for 6 weeks or cyclically for 3 months (2 weeks of each month) are the two regimens most widely used. Other progestins also have been shown to be effective.
CONCLUSIONS: Progestins are highly successful in reversing endometrial hyperplasia caused by ERT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11723414     DOI: 10.1097/00042192-200111000-00006

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  6 in total

1.  The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology.

Authors:  V Phillips; C T Graham; S Manek; W G McCluggage
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

2.  Chromatin composition alterations and the critical role of MeCP2 for epigenetic silencing of progesterone receptor-B gene in endometrial cancers.

Authors:  Yongli Chu; Yanlin Wang; Guanghua Zhang; Haibin Chen; Sean C Dowdy; Yuning Xiong; Fengming Liu; Run Zhang; Jinping Li; Shi-Wen Jiang
Journal:  Cell Mol Life Sci       Date:  2014-02-15       Impact factor: 9.261

3.  Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia.

Authors:  A V Kubyshkin; L L Aliev; I I Fomochkina; Ye P Kovalenko; S V Litvinova; T G Filonenko; N V Lomakin; V A Kubyshkin; O V Karapetian
Journal:  Inflamm Res       Date:  2016-06-16       Impact factor: 4.575

4.  Progestin therapy of complex endometrial hyperplasia with and without atypia.

Authors:  Susan D Reed; Linda F Voigt; Katherine M Newton; Rochelle H Garcia; H Kimberly Allison; Meira Epplein; Diana Jordan; Elizabeth Swisher; Noel S Weiss
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.661

Review 5.  Therapeutic options for management of endometrial hyperplasia.

Authors:  Vishal Chandra; Jong Joo Kim; Doris Mangiaracina Benbrook; Anila Dwivedi; Rajani Rai
Journal:  J Gynecol Oncol       Date:  2015-12-01       Impact factor: 4.401

Review 6.  Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review.

Authors:  Sebastián Carranza-Lira
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.